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SUMMARY
Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML patients are rarely cured by this
therapy perhaps due to imatinib refractoriness of leukemia-initiating cells (LICs). Evidence for this is limited
because of poor engraftment of human CML-LICs in NOD-SCID mice and nonphysiologic expression of
oncogenes in retroviral transduction mouse models. To address these challenges, we generated mice
bearing conditional knockin alleles of two human oncogenes: HIP1/PDGFbR (H/P) and AML1-ETO (A/E).
Unlike retroviral transduction, physiologic expression of H/P or A/E individually failed to induce disease,
but coexpression of both H/P and A/E led to rapid onset of a fully penetrant, myeloproliferative disorder, indi-
cating cooperativity between these two alleles. Although imatinib dramatically decreased disease burden,
LICs persisted, demonstrating imatinib refractoriness of LICs.INTRODUCTION
A number of chromosomal translocations that contribute to
leukemogenesis in humans have been identified (Gilliland,
2002). For example, translocations that lead to the expression
of a constitutively active platelet-derived growth factor beta
receptor (PDGFbR) fusion protein, such as HIP1/PDGFbR (H/P)
(Ross et al., 1998), contribute to the development of chronic
myelomonocytic leukemia (CMML) (Grand et al., 2004). Although
these PDGFbR-driven leukemias are clinically sensitive to imati-
nib therapy (Tefferi and Gilliland, 2007), the leukemias can still
progress to acute myeloid leukemia (AML) or bone marrow
failure over time. Progression to AML in chronic leukemias with
tyrosine kinase mutations is associated not only with resistance
to imatinib but also with additional genetic lesions such as thet(8;21)-associated AML1/ETO (A/E) fusion protein (Golub et al.,
1994; Miyoshi et al., 1991).
Molecularly targeted cancer therapies, such as imatinib, have
revolutionized patient care over the past 20 years. These drugs
target molecular defects specific to cancer cells rather than
simply targeting mitotically active cells. For example, the use
of imatinib in CML patients has led to an enormous reduction
in the 5-year mortality associated with Bcr/Abl-positive CML
(Druker et al., 2006); however, only 5% of patients maintained
on imatinib therapy are considered cured as defined by
a molecular remission (Kavalerchik et al., 2008). In fact, upon
discontinuation of therapy, the disease aggressively relapses
in the majority of patients (Savona and Talpaz, 2008). These
clinical observations suggest that although imatinib eliminates
the bulk of CML cells, this drug probably does not eliminateSIGNIFICANCE
Tyrosine kinase oncogenes contribute to the development andmaintenance of many neoplasms. To understand how these
oncogenes contribute to drug sensitivity and development of neoplasms, realistic mouse models are essential. A condi-
tional knockin allele of the HIP1/PDGFbR tyrosine kinase oncogene that allows for physiologic levels of HIP1/PDGFbR
(single copy, endogenous promoter) at the right time (adult) and place (cell type) is described here. This model allows for
the testing of therapies that target PDGFbR oncogene-activated pathways in immunocompetent animals with leukemia.
Using these animals, we have found that HIP1/PDGFbR;AML1/ETO-expressing leukemia-initiating cells are relatively refrac-
tory to imatinib. These data provide direct evidence that rare leukemia-initiating cells in CML are more resistant to imatinib
treatment than other CML cells.Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc. 137
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state.
The CML-LIC, like normal hematopoietic stem cells (HSCs), is
thought to have not only the properties of self-renewal and multi-
potentiality, but also a relative quiescence compared to the more
differentiated leukemia cells (Kavalerchik et al., 2008). This
quiescence has led to the hypothesis that the LIC is likely to be
refractory to nontargeted therapies, such as chemotherapy or
radiotherapy, which depend upon cell division for their cytotox-
icity. In contrast, targeted therapies, such as imatinib, were
thought to be more likely than standard therapy approaches to
eliminate LICs. Unfortunately, in the case of CML, the latter
does not appear to be the case. Indeed, cell culture data have
suggested that Bcr/Abl-expressing cells are refractory to imati-
nib therapy when quiescent and that awakening these cells
increases their sensitivity to this drug (Jorgensen et al., 2006).
The mechanism of this observed resistance and the in vivo
confirmation of the relative refractoriness of CML-LICs to imati-
nib therapy compared with the bulk of neoplastic cells, however,
have not yet been reported. These types of in vivo studies have
been difficult to accomplish due to poor engraftment of CML
LICs into NOD-SCID mice and limitations inherent in the vari-
ability associated with studying human subjects.
Modeling hematopoietic neoplasias in mice to study effects of
therapies on cancer cells in vivo has also been challenging
because the consequences of oncogene expression are
different depending upon the techniques used to obtain expres-
sion. For instance, retroviral overexpression of A/E in hematopoi-
etic cells leads to the formation of acute leukemias in some
cases but not in others, and this variability might be due, in
part, to expression of different isoforms (Yan et al., 2006). This
heterogeneity in outcome might also stem from variables
inherent to retrovirus-mediated transduction, including copy
number, expression level, integration site, the presence and
identity of cooperating insertional mutations, and the identity of
the infected cells. Furthermore, growth of retrovirally infected
cells might select for rare clones that have the highest levels of
proliferation. In contrast to the retroviral model of A/E, Downing
and colleagues developed a conditional knockin allele of A/E
that was expressed from the mouse Aml1 locus. Conditional
expression of A/E under the control of native regulatory elements
in the locus was never leukemogenic on its own. Treatment of
disease-free conditional A/E knockin mice with the DNA
alkylating mutagen N-ethyl-N-nitrosourea (ENU) resulted in the
development of acute leukemia (Higuchi et al., 2002). These
results suggest that the use of knockin alleles of oncogenes
improves leukemia mouse modeling by achieving more realistic
expression patterns; however, the A/E knockin model was still
not entirely useful to leukemia investigators because these
mice require unidentified cooperating mutations to develop a
neoplastic phenotype.
In contrast to the existence of conditional knockin mouse
models of the transcription factor oncogene A/E (Higuchi et al.,
2002) and other transcription factor oncogenes such as the
MLL translocation fusions (Cano et al., 2008; Chen et al.,
2008), mouse models currently used to study tyrosine kinase
oncogenes have been limited to retroviral transduction and
transplantation assays (Grisolano et al., 2003; Neering et al.,
2007), a nontargeted transgenic of BCR/ABL (Huettner et al.,138 Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc.2000; Jaiswal et al., 2003), and a nonconditional knockin mouse
model of Flt3-Itd mutations (Lee et al., 2007; Li et al., 2008).
Similar to the results described above for A/E, Flt3-Itd knockin
animals demonstrated that knockin alleles of oncogenic tyrosine
kinases likely yield different results than retrovirally expressed
alleles (Lee et al., 2007; Li et al., 2008). Thus, most conclusions
as they relate to oncogene expression-induced leukemias to
date have been based on nonphysiologic expression of onco-
genes. Our understanding of leukemia biology will clearly benefit
from studying the consequences of oncogene expression under
the control of native regulatory elements.
Because a knockin allele of an oncogenic PDGFbR kinase that
is conditionally expressed under the control of native regulatory
elements in adult hematopoietic progenitors is not yet available,
the goals of this study were to generate a conditional knockin
allele of the H/P mutation and examine its ability to drive hemato-
poietic neoplasias. This allele might provide us with a more real-
istic model of X-PDGFbR-driven hematopoietic neoplasias for
investigation of therapies. Another goal of this study was to test
if knocked in tyrosine kinase oncogene alleles can cooperate
with knocked in transcription factor oncogene alleles such as
A/E (Higuchi et al., 2002). Finally, we used these H/P knockin
mice to compare the response of LICs and other neoplastic cells
to imatinib therapy.
RESULTS
Generation of H/P Conditional ‘‘Knockin’’ Mice
To model the human t(5;7) translocation, we engineered the
human H/P cDNA into the mouse Hip1 locus downstream of
a loxP-bracketed transcriptional stop cassette (Hip1LSL-H/P,
Figure 1A). This conditional knockin allele allows use of specific
Cre transgenic mice to guide tissue-specific expression together
with the endogenous mouse Hip1 promoter to regulate the
expression of the oncogenic fusion protein both spatially and
temporally. We targeted ES cells to generate mice carrying the
Hip1LSL-H/P allele (Figure 1B).Hip1+/LSL-H/P mice were born at pre-
dicted Mendelian frequency and exhibited normal growth curves;
however, these mice were distinguishable from wild-type litter-
mates by the presence of gross micro-ophthalmia and cataracts
as seen previously in the heterozygous Hip1+/null mice (Oravecz-
Wilson et al., 2004). The Hip1+/LSL-H/P mice were crossed with
transgenic Mx1-Cre mice. The Mx1 promoter is activated by
interferon, which is induced by treatment with the synthetic
double-stranded RNA, polyinosinic-polycytidylic acid (pIpC)
(Higuchi et al., 2002; Kuhn et al., 1995; Yilmaz et al., 2006). The
pIpC treatment leads to Cre expression in an array of hematopoi-
etic and nonhematopoietic cells, but because the expression of
the knockin allele depends on many of the natural regulatory
elements of the HIP1 locus, we predicted that its expression
would closely mimic that found in the original CMML patient.
Southern blot analyses demonstrated that pIpC-induced recom-
bination occurred in liver, kidney, and spleen but not in brain or
testes (Figure 1C).
Absence of Neoplasia in pIpC-Induced
Mx1-Cre;Hip1+/LSL-H/P Mice
Mx1-Cre;Hip1+/LSL-H/P and Mx1-Cre;Hip1+/+ littermate controls
were treated with pIpC at 6 weeks of age (n = 20 for each
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(A) Schematic of the first 8 of 32 exons of the murine Hip1 genomic locus
(Hip1+), the targeted Hip1LSL-H/P knockin allele generated by homologous
recombination, and the allele with a deleted stop cassette (Hip1H/P) following
Cre-mediated recombination. The following features are indicated: stop
cassette bracketed by loxP recombination sequences (LSL), partial human
H/P cDNA, and cDNA or genomic hybridization probes. Just 30 of the H/P
cDNA is a poly A tail (light gray box) and 30 of this was a neomycin selection
cassette (dark gray box).
(B) Southern blot analysis (genomic probe) of EcoRI-digested DNA from wild-
type and Mx1Cre;Hip1+/LSL-H/P mice.
(C) Southern blot analysis (cDNA probe) of EcoRV-digested DNA from multiple
tissues shows partial recombination in the kidney, liver, and spleen and no
recombination in brain or testis tissue.
(D) Complete blood counts (CBC) from wild-type and single knockin H/P mice
were normal. A cohort of pIpC-treated Mx1Cre;Hip1+/LSL-H/P mice (n = 18) and
Mx1Cre;Hip1+/+ mice (n = 18) were observed until 18 months of age. Bleeds
were taken before induction and then monthly after induction. Averages and
standard deviations (SD) of all 18 mice are reported. No significant differences
were observed between the two groups in WBC counts or any shifts in differ-
entials over the entire time coarse up to the final bleed. At 18 months of age the
mice were euthanized and necropsied to observe any disease either by gross
observation or histologically.
(E) Enlarged spleen (0.27 g) from the youngest morbid Mx1Cre;Hip1H/P (tag
#1156, 3 months old) shows myeloproliferation. Western blot analysis for H/P
expression in this mouse was performed on bone marrow culture from the
same mouse (lane 2) and from its control littermate (lane 1). The bone marrow
cells were cultured for 7 days in monocytic culture conditions prior to analysis
(41). Anti-human HIP1 (UM323), anti-PDGFbR (BD Bioscience), anti-mouse
HIP1 (UM354), and anti-actin (Sigma) polyclonal antibodies were used to
detect the human fusion protein, endogenous mouse HIP1, and actin as indi-
cated. Scale bar represents 600 mm.
(F) A liver tumor from a 9-month-old Mx1Cre;Hip1H/P mouse (tag #1151)
shows a well-differentiated hepatocellular carcinoma histopathology.
Southern blot analysis (cDNA probe) of EcoRV-digested DNA from kidney,genotype) and monitored by peripheral blood analysis for
18 months (Figure 1D). Almost all of the animals survived to
1.5 years of age without gross evidence of disease, although
two moribund pIpC-induced Mx1-Cre;Hip1+/LSL-H/P mice (3 and
9 months of age) were discovered. The 3-month-old had spleno-
megaly with a moderately effaced splenic structure (Figure 1E).
The H/P fusion protein was detectable by western blot of lysates
from cultured bone marrow cells from this mouse (Figure 1E, lane
2). The 9-month-old had a well-differentiated hepatocellular
carcinoma (Figure 1F). Interestingly, the neoplastic liver tissue
exhibited complete recombination of the Hip1LSL-H/P allele, but
the kidney from this mouse maintained a 50% rate of recombina-
tion in the Hip1LSL-H/P allele (Figure 1F). The remaining mice
appeared healthy up to 1.5 years of age without abnormalities
in peripheral blood cell counts (Table S1).
At the experimental endpoint of 1.5 years, the mice were killed
and necropsied for gross abnormalities. Eight pIpC-induced
Mx1-Cre;Hip1+/LSL-H/P mice (47%) and three Mx1-Cre;Hip1+/+
mice (20%) were found to have enlarged spleens (>150 mg)
upon necropsy. The histology of the enlarged spleens showed
signs of myeloproliferation with enlarged red pulp. Myeloprolifer-
ative disorder (MPD) was histologically diagnosed from five of
the H/P (29%) and one of the wild-type (7%) enlarged spleens.
An additional Mx1-Cre;Hip1+/LSL-H/P mouse had a liver tumor
(Table 1). Flow cytometry and methylcellulose analyses of
bone marrow from the 1.5-year-old pIpC-treated Mx1-Cre;
Hip1+/LSL-H/P mice did not display significant abnormalities
(data not shown; see Table S2 available online). Excision of the
floxed stop cassette was detected by polymerase chain reaction
(PCR) in hematopoietic tissue from the 1.5-year-old mice, indi-
cating that the lack of significant disease was not due to selec-
tive loss of cells with the recombined Hip1H/P allele (Figure 1G).
Because the pIpC-treated Mx1-Cre;Hip1+/LSL-H/P mice did
not frequently develop hematopoietic malignancies even after
1.5 years, we conclude that physiologic H/P expression is not
sufficient to cause hematopoietic transformation. These results
are in contrast with evidence from models that rely on retroviral
bone marrow transduction and transplantation (BTT) of tyrosine
kinase oncogenes such as Bcr/Abl (Neering et al., 2007), TEL/
PDGFbR (Grisolano et al., 2003), and H/P. For example, H/P in
the BTT system induces an MPD with full penetrance and latency
of 40–100 days after transplant (Figure S1). Although latencies of
disease onset might be quite variable between different onco-
genes (e.g., Bcr/Abl induced disease with the least latency
between 21 and 28 day after transplant), all three of these onco-
genes are sufficient to induce an MPD similar to CML.
The infrequent occurrence of neoplasms after a long latency in
the mice bearing the H/P knockin allele suggests that additional
genetic events are required to transform hematopoietic cells. To
‘‘normal’’ gross liver, and liver tumor DNA from the second pI-pC induced
Mx1Cre;Hip1+/LSL-H/P (H/P) mouse that was moribund and sacrificed at
9 months of age. Note that the DNA from the kidney was partially recombined
(50%), allowing for demonstration of both alleles, while the liver tumor is fully
(100%) recombined. Scale bar represents 30 mm.
(G) Analysis for recombination in tissues from 18 month old mice demonstrates
that the Hip1H/P allele was not lost over time. NC, negative control wild-type
DNA; PC, positive control for presence of the recombined allele. The 336 bp
band is the recombined allele and the 200 bp band is the wild-type allele.Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc. 139
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Aged Mice
Genotype na Ageb Liver Tumor Lethal dis. Large Spleen Large Thymus Mesenteric Lymphoma Total with dis.
(>150 mg) (>100 mg)
+/+ 7 <1 yr 0 0 0 0 0 0 (0%)
H/P 6 <1 yr 1 2 1 0 0 2 (33%)
+/+ 15 1.5 yr 0 0 3 0 0 3 (20%)
H/P 17 1.5 yr 1 0 8 0 0 9 (53%)
ENU-Treated Mice
+/+ 12 1 yr 0 0 0 0 0 0 (0%)
H/P 24 1 yr 0 7 14 4 1 17 (71%)
a All mice were Mx-1Cre+ and pIpC treated between 6 and 11 weeks of age.
b At 18 months of age, although all non-ENU treated surviving mice were apparently healthy, we did discover at necropsy that 8 of 17 remaining H/P
mice had enlarged spleens compared with 3 of 15 of the wild-type mice (>150 mg).begin to test this hypothesis, 7- to 11-week-old H/P mice were
mutagenized with ENU to induce secondary mutations following
pIpC induction of H/P recombination. A week after pIpC induc-
tion, the mice were treated with G-CSF for 4 days to induce
myeloid proliferation, and the following day the mice were
administered a single mutagenic dose of ENU (50 mg/kg).
Because this dose of ENU efficiently induces only single base
mutations (Breuer et al., 1991), we did not observe any neopla-
sias in mutagenized wild-type control animals as expected (0/12;
Table 1). By contrast, 71% of the H/P-expressing mice died or
developed disease by 10 months after treatment (17/24; Table 1).
Disease was scored as ‘‘present’’ when gross thymic tumors,
splenomegaly, and/or spontaneous death were observed. Inter-
estingly, histological and fluorescence-activated cell sorting
(FACS) analysis of the spleens demonstrated both myeloid and
lymphoid neoplasias, suggesting that the H/P mutation does
not specifically transform cells of the myeloid lineage. Finally, it
remains unknown if disease penetrance in mice bearing the H/P
knockin allele is modified by different genetic backgrounds
because all of the studies presented here were on a pure C57/
BL6 background.
CML-Like MPD in pIpC-Induced H/P;A/E Mice
The A/E mutation has been identified in many human tyrosine
kinase-driven leukemias (Golub et al., 1994; Miyoshi et al.,
1991; Schessl et al., 2005). We therefore tested whether condi-
tional coexpression of the H/P and A/E fusion oncogenes from
their endogenous loci in adult mice led to hematopoietic trans-
formation. A previous report showed that Mx1-Cre-activated
A/E expression from the mouse Aml1 locus is insufficient for
leukemogenesis (Higuchi et al., 2002). Dual conditional knockin
mice were generated by intercrossing Mx1-Cre;Hip1+/LSL-H/P
mice with Aml1+/LSL-A/E knockin mice (Figure 2A). The double
knockin Mx1-Cre transgenic uninduced H/P;A/E mice, which
were genotyped at weaning (Figure S2A), were born and
survived at a significantly lower than predicted Mendelian
frequency (7.5% observed versus 12.5% expected; p < 0.001
Figure S2B), indicating some embryonic or perinatal lethality.
All surviving mice, however, were developmentally normal.
To study the consequences of simultaneous H/P and A/E
expression in adult bone marrow, we treated H/P;A/E mice
with six doses of pIpC every other day beginning at 6 weeks of140 Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc.age. In contrast to wild-type and single knockin mice, 100% of
the induced double knockin (H/P;A/E) mice developed a fully
penetrant, aggressive MPD, some within days of initiation of
pIpC treatment (Figure 2B; Figure S2C). The CML-like disease
was easily identifiable by severe myeloid leukocytosis
(Figure 2D and 2E) and palpable hepatosplenomegaly as early
as 72 hr after the start of pIpC induction (range 3–42 days;
Figure 2F). White blood cell (WBC) counts at the time of eutha-
nasia were increased an average of 25-fold above wild-type
levels with a range of 50–700 K/ml (Figure 2E). Although the white
cell differential demonstrated a reversal of the normal 1:3 neutro-
phil-to-lymphocyte ratio (Figure 2E, right), an increase in abso-
lute numbers of all lineages was also observed. Compared
with wild-type or single knockin animals, spleen and liver weights
of diseased H/P;A/E animals were increased 10-fold and 2-fold,
respectively (Figure 2F, left). Myeloid blasts were never observed
at a frequency greater than 20% in bone marrow cytospins,
precluding a diagnosis of acute leukemia (Figure S2D) (Kogan
et al., 2002).
In addition, histological analysis demonstrated a gross efface-
ment of normal splenic architecture with expansion of the red
pulp (composed of sheets of mature and maturing granulocytic
cells) and disappearance of organized follicles (Figure 2F, right
hand panel). Mutant livers displayed similar mature myeloid cells
surrounding portal cavities and infiltrating the parenchyma
(Figure 2F, right hand panel). Lung sections showed infiltration
of alveolar wall spaces with these same mature myeloid cells
(Figure S2E). Immunohistochemical analysis demonstrated that
the majority of the myeloid cells in the spleen and liver were gran-
ulocytic rather than monocytic because the cells were myeloper-
oxidase positive but nonspecific esterase negative (Figure S3
and data not shown). TUNEL analysis did not demonstrate
changes in the frequency of apoptotic cells. In contrast, the
neoplastic cells were often positive for the proliferation marker
Ki67, whereas normal spleen and liver contained only rare Ki67-
positive cells (Figure S3).
Although kidney, liver, and spleen displayed 50% recombina-
tion of H/P alleles in healthy single H/P knockin mice (Figure 1C),
neoplastic double H/P;A/E knockin spleen samples demon-
strated complete recombination of the H/P allele, suggesting
expansion of cells harboring the recombined allele (Figure 2C).
Recombination of the H/P and A/E stop cassettes was also
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a CML-like MPD
(A) Schematic of the mating scheme that was used to
produce the double knockin mice used in this study.
Also shown are the symbols used to designate the
different genotypes.
(B) The Kaplan-Meier curve depicts disease-free
survival as a function of time in weeks since pIpC
induction. The rapid decline in disease-free survival
of H/P mice at 67 weeks reflects occult abnormalities
discovered at necropsy (Table 1).
(C) Southern blot analysis (cDNA probe) of EcoRV-
digested DNA from multiple tissues from a pIpC-
induced H/P;A/E mouse shows no recombination in
the tail, partial recombination in the kidney, and
complete recombination in a neoplastic spleen.
(D) Peripheral blood smears from control (WT) and
diseased mice (H/P;A/E) are represented. Scale bar
represents 40 mm.
(E) Complete blood counts (CBC) from wild-type (WT;
n = 9), H/P (n = 11), A/E (n = 3), and H/P;A/E (n = 8) mice
were determined prior to pIpC induction (prebleed)
and then after pIpC induction once weekly to deter-
mine onset of disease. Average final WBCs at
necropsy are displayed (left panel). H/P;A/E mice
developed a severe myeloid leukocytosis (right panel;
NE, neutrophil; LY, lymphs; MO, monocytes). Values
are mean ± SD. Asterisk denotes a significant differ-
ence (p < 0.01) compared with WT mice.
(F) Massive hepatosplenomegaly in H/P;A/E mice. All
livers and spleens (left inset is a WT spleen, and right
inset is a H/P;A/E spleen) from H/P;A/E mice were
greatly enlarged at necropsy while kidneys were
normal (WT n = 9, H/P n = 11, A/E n = 3, H/P;A/E
n = 8; mean ± SD; *p < 0.01). Histological analysis of
hematoxylin and eosin-stained spleen and liver tissue
from WT, H/P, A/E, or H/P;A/E mice were examined
(right hand panels). Effacement of the normal follicular
architecture of the spleen and infiltration of the liver
was observed only in the H/P;A/E mice. Scale bar
represents 300 mm.detected in peripheral blood by PCR (data not shown). Bone
marrow cells from diseased H/P;A/E mice readily grew under
monocytic (or myeloid) culture conditions, and the H/P protein
was detected in these cells by western blot (data not shown).
These data indicate that simultaneous activation of the H/P
and A/E oncogenes confers a selective growth advantage to
hematopoietic cells.
We next examined the cellular characteristics of the spleen
and bone marrow from wild-type, single knockin, or double
knockin mice 4 weeks after pIpC induction to more thoroughly
analyze the hematopoietic neoplasia. Spleen cellularity was
sharply elevated in induced H/P;A/E mice (Figure 3A), whereas
bone marrow cellularity was diminished (Figure 3B). In both
tissues, the frequency of Mac-1+Gr-1+ myeloid cells was
increased (Figures 3A and 3B, right hand panels). This expansion
of differentiated myeloid cells was associated with a relative
decrease in frequency of B, T, and erythroid cells in bone marrow
and spleen (Figure S4 and data not shown). Although hematopoi-
etic stem cell (HSC) frequency was reduced in the bone marrow
of both the single H/P knockin mice and the H/P;A/E mice
(Figure 3C, left hand panel), the absolute number of HSCs inthe H/P;A/E spleen was increased (Figure 3C, right hand panel),
consistent with the onset of extramedullary hematopoiesis,
which often occurs in the context of hematopoietic malignan-
cies. The diminished frequency of HSCs in the single H/P
knockin mice was not observed in the 1.5-year old single H/P
knockin mice (Table S2) and was therefore not pursued further
for this study. In addition, the frequency of bone marrow cells
that formed primitive GEMM colonies or GM colonies in methyl-
cellulose was also reduced upon H/P;A/E induction (Figure 3D).
Together, these cellular characteristics are consistent with the
development of a CML-like MPD in induced H/P;A/E mice.
It is possible that the diminished bone marrow HSC frequency
was due to an intrinsic effect of oncogene expression on HSC
maintenance or due to an extrinsic effect of the leukemic cells
on normal HSC survival (or both). To test these possibilities in
the H/P;A/E-expressing mice, we conducted a competitive
bone marrow repopulation experiment. In this experiment,
1,000,000 bone marrow cells from uninduced Mx1Cre;H/P;A/E
or Cre negative control mice (CD45.2) together with 500,000
wild-type cells from recipient-type bone marrow (CD45.1) were
used as donor cells (Figure 4A shows schematic). RecipientsCancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc. 141
Cancer Cell
A Knockin Model of Imatinib Refractory CML(CD45.1) were analyzed for stable peripheral blood chimerism
6 weeks after transplant and then induced with pIpC. As
expected, all of the Mx1Cre;H/P;A/E recipients developed a
CML-like MPD that was grossly and histologically identical to
that of the primary mice (Figure S5). Two weeks after induction
(during early stages of disease), groups of mice from Mx1Cre;
H/P;A/E and control transplants were euthanized, and their
bone marrows were analyzed for HSC distribution (n = 3 each
group). For both groups, HSCs were distributed in the expected
2:1 ratio of CD45.2 donor-type to CD45.1 recipient-type
(Figure 4B). However, the total numbers of recipient and donor-
type HSCs were significantly decreased in the Mx1Cre+;H/P;A/E
recipients compared with Cre-negative controls (Figure 4C).
Together, these data indicate the presence of an extrinsic inhib-
itory effect of the H/P;A/E-expressing CML-like MPD on the HSC
compartment.
We next attempted to transplant the CML-like MPD from H/P;
A/E mice into secondary recipients. The direct transfer of unfrac-
tionated primary neoplastic cells from diseased H/P;A/E mice to
immunocompromised or syngeneic recipient mice was highly
inefficient, consistent with prior studies that have found MPDs
relatively difficult to transplant (Kogan et al., 2002; Lee et al.,
Figure 3. Abnormal Immunophenotype of Hema-
topoietic Cells from the Bone Marrow and Spleen
of H/P;A/E Mice
(A, B) Single cell suspensions of bone marrow and spleen
cells from pIpC-induced Mx1-Cre transgenic mice
(average 3 weeks after induction) that were either WT, H/P,
A/E, or H/P;A/E were analyzed by flow cytometry. Values
in all the bar graphs are mean ± SD. Representative flow
cytometry profile of forward and side scatter of spleen
cells (A) and bone marrow cells (B). These profiles illustrate
the presence of a distinct, uniform population of enlarged
cells (box) in the spleen and bone marrow of H/P;A/E mice.
Representative profile of the myeloid immunophenotype
illustrates a significant increase in both mature granulo-
cytic (Gr1+/Mac1+) and monocytic (Gr1lo/Mac1+) popula-
tions (A, B, left lower panels) in H/P;A/E mouse spleen
and bone marrow. For WT (white bar), H/P (black bar),
and A/E (light gray bar) mice, n = 4. For H/P;A/E (dark
gray bar) mice, n = 10. Asterisk denotes a significant differ-
ence (p < 0.01) between H/P;A/E mice and WT, H/P, or A/E
mice.
(C) The frequency (%) of CD150+CD48-CD41-Sca-1+c-kit+
HSCs in the bone marrow of H/P;A/E (dark gray bars) mice
was significantly reduced. Asterisk denotes a significant
difference between H/P;A/E and WT mice (p < 0.01).
(D) The frequencies of CFU-GEMM and CFU-GM colonies
were significantly diminished in the bone marrow from
H/P;A/E mice (dark gray bar) compared with WT (white),
H/P (black), or A/E (light gray) mice.
2007; Sirard et al., 1996). For example, when
sublethally irradiated (1 3 240 rad), NOD/
SCID-IL2Rg mice were retro-orbitally injected
with unfractionated bone marrow cells (2 3
106) from H/P knockin, A/E knockin, or diseased
double H/P;A/E knockin animals. None of the
recipients displayed evidence of disease for up
to 20 weeks (data not shown). In lethally irradi-
ated syngeneic CD45.1 recipients, up to 6 3
106 whole bone marrow cells from multiple diseased donors
(n = 4) were also highly inefficient at transplanting the disease
(Table 2, ‘‘vehicle’’). Similar results were obtained with unfractio-
nated splenocytes. The relative inability of cells from animals
with H/P;A/E-induced disease to transfer disease upon trans-
plantation is consistent with the idea that the vast majority of
CML cells have a limited capacity to proliferate (Kavalerchik
et al., 2008; Savona and Talpaz, 2008; Sawyers et al., 1992).
Furthermore, these data also support the categorization of this
hematopoietic neoplasia as a CML-like MPD rather than a trans-
plantable leukemia (Kogan et al., 2002).
To begin to identify the LIC from the diseased mice, we per-
formed transplant experiments with FACS-purified HSCs.
Although transplantation of HSCs from these mice did not trans-
fer a florid CML-like MPD into syngeneic recipients, these cell
transfers resulted in rapid death after transplant in a high
frequency of recipients (Table 2). This was despite the fact that
sufficient ‘‘radio-protective’’ bone marrow cells were mixed
with the purified HSCs for transplant success. Histological anal-
ysis of the spleens from the mice that received the purified
HSC transplantation demonstrated myeloid infiltrates that were
consistent with an MPD. The inability to transfer a full blown142 Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc.
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is consistent with the presence of an extrinsic inhibitory effect of
the diseased cells on normal cell hematopoiesis (Figure 4C).
These data also suggest that tumorigenic cells (or LICs) from
the diseased H/P;A/E mice might be present in the phenotypic
HSC fraction.
Imatinib Treatment Reduces Leukemic Burden,
but Not LICs
To determine whether PDGFbR signaling from H/P was critical
to the maintenance of the H/P;A/E-induced neoplasia, a group
of diseased mice were treated with imatinib or vehicle for 10–
12 days by intraperitoneal injection (n = 4 imatinib, n = 3 vehicle).
All vehicle-treated H/P;A/E-induced mice exhibited progressive
hepatosplenomegaly, effacement of splenic architecture, and
myeloid infiltration of their livers and lungs. Imatinib therapy did
not appear to exert any discernible effects on wild-type animals
Figure 4. Although an H/P;A/E-Expressing MPD Results from an
Intrinsic Transforming Effect, There Is an Extrinsic Inhibitory Effect
on Normal BM HSC Frequency
(A) Irradiated (CD45.1) recipients were transplanted with twice as many donor
(CD45.2) Mx1-Cre;H/P;A/E or control bone marrow cells to recipient (CD45.1)
bone marrow cells. Six weeks after transplantation, recipient mice were
treated with pIpC for 2 weeks to induce recombination. Mice were bled
4 weeks after induction to monitor disease progression. All of the mice trans-
planted with the Mx1-Cre;H/P;A/E bone marrow were with splenomegaly and
leukocytosis similar to the primary disease, whereas the H/P;A/E Cre negative
donors were disease free (Figure S5).
(B) Cells from bone marrow 4 weeks after pIpC induction were analyzed for
frequency of CD150+CD48-CD41-Sca-1+c-kit+ (SLAM HSCs) donor versus
recipient cells. The donor cells accounted for 61% of HSCs in recipient
mice as expected, whether the mice had been transplanted with control donor
cells or H/P;A/E donor cells. Values represent mean ± SD of three mice per
treatment.
(C) The absolute number of both donor-type (H/P;A/E) and recipient-type (WT)
bone marrow HSCs decreased significantly in HP/AE recipients when
compared with control recipients. The total number of HSCs (donor-type +
recipient-type) was also drastically reduced. Values represent mean ± SD of
three mice per treatment. Asterisk denotes a significant difference (p < 0.05)
compared with control recipients.(data not shown). In contrast, imatinib treatment of H/P;A/E-
induced mice led to a rapid response as evidenced by reduction
of WBCs to wild-type levels (p = 0.01, Figure 5A). Upon
necropsy, significant decreases in spleen (p = 0.0005) and liver
(p = 0.004) size were also observed (Figure 5B and data not
shown). Histologically, splenic architecture was normalizing,
and the liver appeared free of myeloid infiltrates (Figure 5C).
This rapid hematological response to imatinib is consistent
with that observed following imatinib treatment in humans with
CML (Savona and Talpaz, 2008) and in mice with retroviral
expression of tyrosine kinases such as BCR/ABL (Wolff and
Ilaria, 2001) and TEL/PDGFbR (Grisolano et al., 2003).
We next analyzed the effect of imatinib on HSC frequency in
H/P;A/E mice. Compared with vehicle-treated mice, bone marrow
from imatinib-treatedmicedisplayed a restoration ofnearlynormal
HSC frequency in bone marrow (0.0026 ± 0.0018, p = 0.05;
Figure 5D and data not shown). Interestingly, in contrast to the
reduction observed in spleen cellularity, bone marrow cellularity
was not immediately restored, presumably due to the depletion
of CML-like MPD cells from the bone marrow (Figure 5B). The
increase in bone marrow HSC numbers concomitant with the
depletion of neoplastic cells suggests the presence of a differential
effect of imatinib on bulk tumor cells as compared to HSCs.
In order to begin to determine whether imatinib affected the
frequency of LICs, we transplanted unfractionated bone marrow
from vehicle- or imatinib-treated H/P;A/E mice into lethally irradi-
ated syngeneic recipients along with a radioprotective dose
of 200,000 wild-type bone marrow cells. We predicted that
imatinib therapy would eliminate the limited transplantability of un-
fractionated bone marrow. Transplants were performed after 10–
12 days of imatinib therapy, when imatinib-treated mice displayed
Table 2. Imatinib Does Not Eliminate LICs fromH/P;A/E CML-like
Disease
Donor
Cell No. Treatmenta Donor N
Recipients with
DiseasebDiseased/Total (%)
Whole Bone Marrow (WBM) Transplants
100,000 Vehicle 2 1/8 (12%)
500,000 Vehicle 2 0/10 (0%)
2,000,000 Vehicle 3 1/14 (7%)
6,000,000 Vehicle 2 0/8 (0%)
100,000 Imatinib 3 3/14 (21%)
500,000 Imatinib 3 5/14 (36%)
2,000,000 Imatinib 3 7/13 (54%)
Hematopoietic Stem Cell (HSC) Transplants
50 Vehicle 1 1/5 (20%)
10 Vehicle 1 3/5 (60%)
5 No Rx 1 1/7 (14%)
50 Imatinib 1 5/5 (100%)
10 Imatinib 1 5/5 (100%)
a H/P;A/E CML-like diseased mice were treated for 10–14 days with ima-
tinib or vehicle prior to transplant of their bone marrow cells into lethally
irradiated syngeneic recipient mice. WBM or FACS isolated HSCs were
cotransplanted with 200–400,000 wild-type bone marrow cells.
b Fraction of recipients with overt CML-like MPD or rapid death after
transplant. All of the HSC transplanted mice died rapidly after transplant
and were found to have evidence of an MPD.Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc. 143
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the Neoplasia
Values in all the bar graphs are mean ± SD.
(A) Imatinib normalized WBCs after 10 days of treatment (*p =
0.01, vehicle versus imatinib).
(B) Imatinib-treated mice exhibited markedly reduced spleen
cellularity (*p = 0.01, vehicle versus imatinib), but bone marrow
cellularity was not immediately normalized.
(C) Imatinib treatment began to restore splenic architecture
and cleared myeloid infiltrates from the liver. Scale bar repre-
sents 300 mm.
(D) The frequency (%) of HSCs was partially rescued in the bone
marrow (p = 0.05, imatinib versus vehicle) but not in the spleen.
Splenic HSC frequency was increased in imatinib-treated mice
(presumably because leukemic burden was dramatically
reduced, increasing the frequency of normal HSCs in the
spleen), but the difference was not statistically significant. +/+
indicates untreated wild-type mice (n = 7); vehicle, vehicle-
treated pIpC-induced H/P;A/E mice (n = 3); imatinib, imatinib-
treated pIpC-induced H/P;A/E mice (n = 4).normalized WBC counts. Regardless of the transferred cell
number,bone marrowcellsand splenocytes from imatinib-treated
mice were consistently more likely to transfer disease than cells
from vehicle-treated mice (Figure 6A, Tables 2 and S3). The recip-
ient disease was grossly and histologically similar to that in the
donors, and no recipients showed evidence of progression to
accelerated or blast crisis phases of the disease (Figure 6B). The
disease in recipient mice remained hematologically sensitive to
imatinib therapy (Figure 6B), indicating that the transferred cells
did not represent imatinib-resistant clones from the donor
animals. The increased transplantability of bone marrow LICs in
H/P;A/E mice after imatinib treatment contrasted dramatically
with the reduced neoplastic burden in these mice and suggested
that LICs are less sensitive to imatinib thanother neoplastic cellsof
the MPD. Further evidence for this refractoriness of the LICs was
accumulated when a rapid return of the MPD disease state was
observed following withdrawal of imatinib from H/P;A/E-express-
ing mice that were put into remission with imatinib therapy (data
not shown). For example, we have continuously treated H/P;A/E
mice for up to 26 days with imatinib and found that upon with-
drawal of imatinib we have observed a return of disease.
Cleardifferences in long-term multilineage reconstitution activity
were also evident between recipients of vehicle- and imatinib-
treated bone marrow samples (Figure 6C). Only 60% of recipients
of vehicle-treated bone marrow cells showed long-term multiline-
age reconstitution by donor cells, confirming the decrease in HSC
frequency inuntreated, inducedH/P;A/E mice (Figures3C and 5D).
In contrast, almost all recipients of bone marrow cells from imati-
nib-treated mice showed long-term multilineage reconstitution
(Figure 6C). This correlation of increased functional HSC activity
(reconstitution) with the increased transplantability of the MPD in
imatinib-treated mice is additional evidence (to the HSC transplant
data) that the LIC is contained in the HSC fraction.
Although we have not yet definitively purified the LIC in these
mice, the evidence thus far indicates that LICs might be found in
the HSC compartment and are relatively refractory to imatinib.144 Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc.Interestingly, FACS-isolated HSCs from imatinib-treated mice
upon transplantation into irradiated mice more frequently led to
early lethality with an MPD compared with HSCs from vehicle-
treated mice (Table 2), suggesting that the increased bone
marrow transplantability observed in the imatinib-treated mice
(Figure 6) might not just induce a change in LIC frequency but
might also modulate their tumorigenicity.
A few possible mechanisms for how the LICs might be insensi-
tive to imatinib while the bulk tumor cells readily respond to
imatinib include the following: lack of H/P kinase inhibition in
LICs due to low intracellular levels of imatinib despite high doses
of drug delivered, lack of expression of the H/P protein in the
LICs despite recombination, extremely high levels of H/P expres-
sion that overwhelm ‘‘therapeutic’’ levels of the drug, or lack of
addiction of these cells toH/P due toquiescenceorother unknown
‘‘context’’ factors.Wehavegatheredsomeevidence that indicates
that H/P-expressing cancer cells may or may not be addicted to
H/P signaling depending on the milieu they are in. For example,
H/P-expressing Ba/F3 cells (similar to BCR/ABL-expressing
Ba/F3 cells) are sensitive to imatinib (‘‘addicted’’) in the absence
of IL-3; however, when IL-3 is present, the survival of these cells
in the presence of imatinib is no different than wild-type Ba/F3 cells
(Figure S6). In this case we know that the H/P protein is expressed
in the cells in the presence or absence of IL-3 so the relative resis-
tance is not due to lack of H/P expression and instead is due to IL-3
induced environmental changes that cure the cells of their H/P
addiction.Untilweare able topurifyenoughLICs fromH/P;A/E-ex-
pressing mice to characterize them, the precise mechanism of
their imatinib refractoriness in vivo remains to be determined and
the above list of possibilities comprise only a subset of avenues
for future investigation of this complex issue.
DISCUSSION
The role of activating mutations of receptor tyrosine kinases
(RTKs) in hematopoietic malignancies is well-established.
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Also Increases the Frequency of LICs
(A) Graded doses of 1 3 105 to 2 3 106 whole bone marrow
cells (WBM) from pIpC-induced H/P;A/E CD45.2 mice that
were treated with vehicle (n = 4 donors, 38 recipients) or imatinib
(n = 3 donors, 40 recipients) for 7–10 days were transplanted
into lethally irradiated CD45.1 recipients along with 2 3 105
wild-type CD45.1 bone marrow cells. Recipients of bone
marrow cells from imatinib-treated mice developed CML at a
greater frequency than recipients of vehicle-treated bone marrow
cells.
(B) Representative peripheral blood smears of pIpC-induced H/P;
A/E donor mice treated with vehicle displayed an abundance of
mature granulocytes (upper left, arrows), which were greatly
reduced in imatinib-treated mice (lower left). This CML-like MPD
was transplantable, with some recipients of vehicle- (middle,
top) and imatinib-treated (middle, bottom) WBM developing
a similar disease. Note the predominantly mature granulocytic
cells in the bottom panels and the absence of blasts. The primary
mice that were treated with imatinib displayed the most trans-
plantable disease and the disease remained sensitive to imatinib
treatment (right hand panels). Scale bar represents 30 mm. Values
in all the bar graphs are mean ± SD.
(C) WBM from imatinib-treated mice more frequently gave rise
to multilineage reconstitution (donor myeloid, B, and T cells) at
12 weeks after transplantation compared with vehicle-treated
mice (at 4 weeks: n = 29 for vehicle, n = 27 for imatinib; at
12 weeks: n = 27 for vehicle, n = 18 for imatinib). Reconstitution was defined as the presence of greater than 0.3% donor type CD45.1 marker in B (B220),
T (CD3), and myeloid (Mac1, Gr1) lineages. Black bars indicate multilineage reconstitution of Cre-negative H/P;A/E (control) bone marrow recipients (n = 15).PDGFßR is one such RTK that is a frequent target in myeloid
leukemias. More than 15 different translocations have been iden-
tified in human CMML patients that lead to constitutively active
fusion variants of PDGFßR (Curtis et al., 2007). Accumulating
evidence suggests that all PDGFßR-containing translocations
share many properties and are functionally interchangeable.
For example, one such translocation, t(5;7)(q33;q11.2), fuses
the majority of theHIP1 gene to the transmembrane and catalytic
domains of the PDGFßR gene (Ross et al., 1998). Like all of the
other PDGFbR fusions, the H/P fusion protein is a constitutively
active tyrosine kinase that is able to transform hematopoietic
cells to factor-independent growth in culture (Ross et al., 1998)
and activate the PI3K, MapK, PLC-gamma and STAT5 pathways
(Ross and Gilliland, 1999). The role of these oncogenes in vivo
has only been studied using the retroviral bone marrow trans-
duction and transplantation assays. In the current study, we
employed a previously described knockin strategy (Higuchi
et al., 2002) that couples a loxP bracketed transcriptional stop
cassette with an inducible Cre transgene to generate a mouse
in which lineage-specific expression of H/P can be temporally
and spatially controlled. This strategy allows us to bypass any
embryonic lethality that results from the expression of H/P (Ora-
vecz-Wilson et al., 2004) and to directly determine the develop-
ment of disease in the adult mouse in the presence or absence of
other genetic lesions such as a conditional A/E knockin allele
(Higuchi et al., 2002).
Following the generation of the Mx1-Cre;Hip1+/LSL-H/P mice,
we found that these mice did not frequently develop hematopoi-
etic malignancies following pIpC induction even after 1.5 years.
H/P expression is, therefore, not sufficient to cause cancer,
though a minority of mice did exhibit enlarged spleens and liver
tumors, suggesting that H/P expression increases the risk ofcarcinogenesis. This finding contrasts starkly with BTT assays
where retroviral expression of tyrosine kinase oncogenes such
as H/P (Figure S1), TEL/PDGFßR (Grisolano et al., 2003), and
BCR/ABL (Neering et al., 2007) induced a MPD similar to CML.
Importantly, because healthy, nonneoplastic tissues (kidney,
liver, spleen) from pIpC-treated Mx1-Cre;Hip1+/LSL-H/P mice
maintained Hip1H/P alleles (Figure 1G), the possibility that
Hip1H/P-containing cells were selected against over time is an
unlikely explanation for the lack of disease after 1.5 years.
Because use of endogenous regulatory elements to express
the H/P oncogene did not lead to the MPD observed following
retroviral expression of tyrosine kinase oncogenes, the cell type
and/or oncogene levels are seemingly key variables to control
when developing mouse models of human cancers.
In contrast to the finding that expression of H/P alone did not
result in transformation of hematopoietic cells in vivo, coinduc-
tion of H/P with A/E led to a florid MPD within days of induction.
Thus, contrary to the BTT models of tyrosine kinase oncogene
and A/E oncogene cooperation that yield longer disease latency
and predominantly acute leukemia (Grisolano et al., 2003;
Schessl et al., 2005), this murine model provides direct evidence
that expression of A/E in adult myeloid progenitors in vivo does
not completely block differentiation but instead cooperates
with H/P to induce an explosive myeloproliferative neoplasm.
Moreover, these data confirm that A/E-induced leukemia is
a multistep process, in which secondary genetic alterations,
such as H/P fusion protein generation, cooperate with A/E to
induce full transformation. This report demonstrates that
a human oncogene can indeed cooperate with the A/E knockin
allele to produce transformation (Higuchi et al., 2002).
Although a clear hematologic response to imatinib was
observed in these double knockin mice, transplant and drugCancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc. 145
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nated by this therapy. This H/P;A/E disease model highlights the
need for therapies that not only target oncoproteins but also
preferentially kill leukemogenic cells. The mechanism(s) of resis-
tance of LICs to imatinib therapy is not yet understood, but
possibilities such as limited intracellular drug levels in the LIC,
limited expression of the oncogene, relative quiescence, or
lack of addiction of the LIC to the oncogene are all currently
under investigation. It will be important to determine if the LICs
depend upon the initiating H/P oncogene signals for survival. If
the LIC is not dependent upon, or cannot be manipulated to be
dependent upon, the H/P activity, then therapeutic variations
on the imatinib therapy theme will be ineffective.
These mice model the neoplastic role of the growing family of
PDGFbR human translocations in vivo more accurately than
before by using a conditional knockin technology. Furthermore,
these experiments provided intriguing insights into how the
different ways used to model leukemia in mice influence
outcomes and conclusions. We expected that activation of
a single copy of H/P cDNA knocked into the endogenous Hip1
locus in the adult mouse would be sufficient to induce a chronic
MPD. In addition, based on the report by Grisolano et al. (2003),
we expected that coinduction of A/E with this H/P allele would
result in an increased frequency or severity of the H/P-induced
disease and would inhibit myeloid differentiation leading to acute
leukemia. To our surprise, however, a very low frequency of
neoplasia was observed in the single H/P knockin mice, and
a shockingly high frequency (100% penetrance) and an essen-
tially absent disease latency of an explosive MPD (rather than
acute leukemia) was observed in the double knockin mice.
This observation directly counters the prevailing idea that A/E
functions via prevention of hematopoietic differentiation (Reilly,
2003). If this notion were true, the H/P;A/E knockin mice would
be immediately blastic and have impaired differentiation. These
findings raise the possibility that modeling leukemogenic events
under the most genetically realistic conditions might help us
identify environmental or genetic triggers that lead to the devel-
opment of CML accelerated phase or frank blast crisis.
In sum, the conditional activation of H/P in the hematopoietic
system of adult mice leads to an explosive, mature, imatinib-
sensitive MPD when coexpressed with A/E. Importantly, LIC
activity was persistent in induced H/P;A/E mice following imati-
nib treatment because their bone marrow was able to transplant
this imatinib-sensitive MPD more readily than vehicle-treated
mice. This model will therefore serve as an invaluable tool for
in-depth studies of the therapeutic effect of PDGFbR (imatinib,
MAPK inhibitors, rapamycin) and A/E (trichostatin A, SAHA)
inhibitors as well as allow for further rigorous in vivo characteriza-
tion of the cellular and molecular mechanisms of hematopoietic
transformation and drug resistance.
EXPERIMENTAL PROCEDURES
Generation of Conditional H/P Knockin Mice
The conditional H/P knockin allele, Hip1LSL-H/P, was generated by modifying
the original H/P knockin target vector that contained a human H/P cDNA in
frame with murine Hip1 exon 2 (Oravecz-Wilson et al., 2004). Two custom
vectors were constructed with desired multiple cloning sites (designated
AMP1 with SpeI, EagI, EcoRI, NotI/EagI, BamHI, and SalI sites; and AMP2
with NotI, KpnI, HindIII, and SalI sites). The 50 NotI/BamHI 8.2 kb fragment146 Cancer Cell 16, 137–148, August 4, 2009 ª2009 Elsevier Inc.from the original H/P knockin vector was subcloned into the EagI/BamHI sites
of AMP1 and named N/B7+KI. Subsequently, the SpeI/EcoRI 7.2 kb fragment
from N/B7+KI was ligated into the EcoRI/EcoRI 4 kb subclone from the original
HIP1/PDGFR knockin target vector and into the AMP1 vector digested with
SpeI and EcoRI (named p1N/RI/RI 50). Next, a 1.5 kb DNA fragment containing
a transcription termination stop cassette flanked by loxP sites was inserted, as
an AscI cassette, 50 to the HIP1/PDGFR cDNA into the KpnI site of HIP1’s intron
2 (KpnI site modified to AscI by the paired oligos: 50-AACATTGGCGCGCC
ACAAGTCGTAC-30 and 50-GACTTGTGGCGCGCCAATGTTGTAC-30) and
designated as p1N/RI/RI 50 stop. This stop cassette contains the SV40 polya-
denylation signal, thus preventing full-length transcripts from being made until
the stop cassette is removed by Cre recombinase. In addition, an ATG transla-
tion start site and 50 splice donor are encoded to prevent correct expression of
the HIP1/PDGFR fusion due to downstream transcription. The 30 half of the
target vector was constructed in the AMP2 vector by first subcloning the 4 kb
HIP1 exon 6 and 7 Hind H/B subclone into the HindIII site of AMP2 (designated
p2H4). A PGK-neomycin NotI/KpnI cassette lacking loxP sites was generated
by PCR using the original target vector as a template and the following primers:
50-TTTGCGGCCGCTAGGTCTGAAGAGGAGTTTAC-30 and 50-TTTGGTACC
ATTAAGGGTTCCGGATCGATC-30. This NotI/KpnI neo PCR product was
subcloned into p2H4 50 of the HIP1 genomic DNA (named p3H4neo). The final
conditional H/P knockin target vector was generated by subcloning the
p3H4neoNotI/SalI 5.5-kb fragment into the corresponding sites in p1N/RI/RI50
stop so as to fuse the neomycin resistance cassette and HIP1 30 genomic DNA
to the 30 end of the polyadenylation signal for the H/P cDNA. The final targeting
vector was 21.5 kb. Electroporation into ES cells and screening by Southern
blot for clones that were correctly targeted with the 30 genomic probe was
performed as described (Oravecz-Wilson et al., 2004).
Southern Blot Analysis
Southern blot analysis to distinguish the targeted Hip1LSL-H/P allele and the
wild-type allele was performed with the 30 probe as described for the Hip1null
allele (Oravecz-Wilson et al., 2004). For recombination of the targeted allele,
a hHIP1 cDNA probe (‘‘50 probe’’ encompassing HIP1 sequences up to the
internal EcoRI site [nt 1260]; Figure 1) was used under the same conditions
as those used for the 30 genomic probe.
Double and Triple Transgenic Mice
Double transgenic Mx1-Cre;Hip1+/LSL-H/P mice were generated by crossing the
Hip1+/LSL-H/P mice with mice transgenic for the Mx1-Cre gene (obtained from
Jackson Labs [Kuhn et al., 1995]). Triple transgenic Mx1-Cre;Hip1+/LSL-H/P;
Aml1+/LSL-A/E mice were generated by crossing the Mx1-Cre;Hip1+/LSL-H/P
mice with Aml1+/LSL-A/E mice (Higuchi et al., 2002). Expression of Cre recombi-
nase was induced by injecting mice intraperitoneally with 250 mg pIpC (Sigma,
St. Louis, MO) in 100 ul PBS at 2-day intervals for 2 weeks as previously
described (Yilmaz et al., 2006). For this study, a total of 69 triple transgenic
mice were generated and 17 (25%) had spontaneous recombination due to
endogenous interferon mediated Mx1-Cre activation. We conclude this
because double knockin mice that were Mx1-Cre negative never underwent
recombination. Mice were mated onto a C57Bl/6 genetic background. Mice
were housed in the Unit for Laboratory Animal Medicine at the University of
Michigan under specific pathogen-free conditions and were monitored regu-
larly for evidence of disease and abnormal peripheral blood cell counts. All
mouse experiments were conducted after approval by the University of Mich-
igan Committee on Use and Care of Animals.
Hematopoietic Analysis
Induced cohorts of 22 Mx1Cre; Hip1+/LSL-H/P and 23 Mx1Cre; Hip1+/+
littermate animals were bled on a monthly basis for determination of
CBCs. Numbers were pooled from each time point. Induced double H/P;A/E
knockin mice were bled on a weekly basis. Blood was collected into a tube
containing EDTA (Sarstad) and analyzed with an 850 HEMA-VET machine
(CDC Technologies).
For the time course of peripheral smears (Figure 2SC) from the double
knockin mice, mice were prebled by submandibular bleed prior to treatment
with pIpC. Twenty-four hours after treatment, daily tail bleeds were initiated.
Smears were stained with Wright-Giemsa.
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from bone marrow and spleen were performed as described previously (Yilmaz
et al., 2006). The total number of CD150+CD48-CD41-Sca-1+c-kit+ cells (HSCs)
per mouse was calculated based on the frequency of this population in the bone
marrow and spleen, the cellularity of the spleen and long bones, and the
assumption that 15% of all bone marrow is within the long bones. Blood and
other tissues do not contribute significantly to the overall size of the HSC pool.
PCR Genotyping
Mouse tail DNA was used for PCR detection of the various germ line alleles.
Hip1LSL-H/P specific primers were 50EcoRI (50-CTGAGAGCCAGCGGGTTGT
GCTGCAGCTGA-30) and 30EcoR1 (50-CTCCTTTAGCTTGCTATATCGCTGTT
CATTGGC-30). Cre allele primers were IMR567 (50-ACCAGCCAGCTATC
AACTCG-30) and IMR568 (50-TTACATTGGTCCAGCCACC-30). Aml1 primers
were Int3.up (50-ATCAAATGATGACGACGG-30), Ex5.low (50-TGATGGCTCTA
TGGTAGGTGG-30), and Int4.low (50-CAGTTTAGGAAAACGGTGG-30 ). The
expected product sizes for Hip1LSL-H/P and Cre products were 200 base pairs.
The Aml1 expected product (Int3.up and Int4.low primer pair) was 596 base
pairs and, the A/E knockin product was 378 base pairs (Ex5.low and Int4.low
primer pair). Pretreatment of 2 ml (100 ng/ml; 200 mg total) of DNA with 5 ml
gene releaser (Bioventrue) was performed.
PCR analysis for Hip1LSL-H/P recombination to Hip1H/P (Figure 1G) was per-
formed as follows. Genomic DNA was isolated from lysed peripheral blood
samples or organs using standard protocols. Recombination of the floxed
stop cassette was detected with the following primers: 50-CTATCCAAGG
GACCTGATGG-30 and 50-GCCAGTCCAAGGTGGATTTA-30. The PCR condi-
tions were as follows: 7 min at 94C, 35 cycles of (30 s at 94C, 1 min at
55C, 1 min at 72C), and 7 min at 72C. The predicted recombined product
was 336 base pairs, whereas the wild-type product was predicted at
200 base pairs. The nonrecombined product, which contained the entire stop
cassette, was 2 kilobases and not amplified under these conditions. PCR anal-
ysis for A/E recombination was performed as described previously (Higuchi
et al., 2002).
Histologic Analysis
Tissue obtained at necropsy was fixed in 10% formalin/PBS. Paraffin embed-
ding and standard hematoxylin and eosin staining were performed by the
University of Michigan Cancer Center Histology Core or Histoserv. MPO stain-
ing was carried out on deparaffinized and hydrated sections (xylene followed
by 100%–50% EtOH). Antigen was retrieved with citrate buffer followed by
incubation of the slide with 10% goat serum block and primary antibody (poly-
clonal anti-MPO, Abcam). Slides were blocked for endogenous peroxidase
with 0.3% peroxide. The secondary antibody was biotinylated goat anti-rabbit
(1:200, Jackson Immuno Research). The signal was amplified using the ABC
kit (Pierce) and visualized with the DAB kit (Vector Labs). TUNEL assay was
performed using the In Situ Cell Death Detection Kit (Roche), and nonspecific
esterase staining was achieved with the nonspecific esterase staining kit
(Sigma) following the manufacturer’s instructions.
Imatinib Experiments
For the mouse treatment experiments, imatinib mesylate capsules (Novartis,
100 mg) were crushed and dissolved in sterile PBS with 10% DMSO at
a final concentration of 20 mg/ml. The solution was filtered through a 0.1 uM
syringe tip filter (Millipore). Mice were injected intraperitoneally once daily
with 100 mg/kg. Mice were treated in pairs (vehicle or imatinib) until a complete
hematologic response (normalized WBC) was observed in the imatinib-treated
mouse (7–10 days), and then both the vehicle and imatinib-treated mice bone
marrow was transplanted into irradiated syngeneic lethally irradiated Ly5.2
recipient mice as described previously (Yilmaz et al., 2006).
ENU Mutagenesis
Seven- to eleven-week-old Mx1-Cre-positive H/P or wild-type mice were
intraperitoneally injected six times with 250 mg pIpC at 2 day intervals. Mice
were then subcutaneously injected with four doses of 1 mg G-CSF followed
by a single IP dose of 50 mg/kg ENU as described previously (Higuchi et al.,
2002). Mice were then observed for disease for 11 months.SUPPLEMENTAL DATA
Supplemental Data include six figures and three tables and can be found with
this article online at http//www.cell.com/cancer-cell/supplemental/S1535-
6108(09)00181-0.
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